Curacle Co., Ltd.

As of June 30, 2026, Curacle Co., Ltd. carries a market capitalization of 266.16B, placing it among publicly traded companies globally. Its enterprise value stands at 254.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Curacle Co., Ltd. has 21.92M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 29.56, and the price-to-book ratio stands at 5.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 30.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 254.31B versus a market cap of 266.16B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Curacle Co., Ltd. maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.80, indicating elevated leverage, while an interest coverage ratio of -9.79 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Curacle Co., Ltd. posted a negative return on equity (ROE) of -22.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.56, reflecting losses generated across the asset base. The company generates approximately 263.70M in revenue per employee across its workforce of 31.25, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Curacle Co., Ltd.'s stock has gained approximately 51.57% over the past 52 weeks. The 50-day moving average sits at 10,027.00, while the 200-day moving average is 12,136.25.

Over the twelve months ended June 30, 2026, Curacle Co., Ltd. generated 8.24B in revenue and converted that into -7.59B in net income, yielding earnings per share of -377.48. EBITDA reached -7.58B, while operating income came in at -8.18B.

As of June 30, 2026, Curacle Co., Ltd. holds 22.96B in cash and equivalents against 11.11B in total debt, resulting in a net debt position of 1.10B. Total book value stands at 46.70B, with working capital of 11.49B providing operational flexibility.

Curacle Co., Ltd. produced -9.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30.31M in capital expenditures, free cash flow totaled -9.51B - equivalent to -474.19 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -99.26 and net profit margin of -92.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.20, meaning Curacle Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Curacle Co., Ltd.'s most recent stock split took place on July 7, 2025 with a 346:407 split ratio.

As of June 30, 2026, Curacle Co., Ltd. has an Altman Z-Score of 9.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.